comprehensive -WSS

comprehensive

author：entertainment 2025-08-28 13:05:53 - browse：4384

ANDREW YATES/AFP via Getty Images

WASHINGTON — A federal judge in Delaware on Friday ruled against AstraZeneca in a case challenging the constitutionality of Medicare’s new drug price negotiation program.

Colm Connolly, chief judge of the U.S. District Court of Delaware, ruled against the company on all its major arguments. He wrote that AstraZeneca had not proved that Medicare’s new drug price negotiation program jeopardizes its constitutional property rights, and that the company didn’t have standing to challenge the guidance Medicare issued to implement the program.

The case is the first of a slew of cases filed by the pharmaceutical industry and its allies to be decided at the district court level. The Delaware ruling is a blow, as several of the other cases made similar arguments about how the program violates drugmakers’ constitutional property rights.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Patients' immediate access to test results puts radiologists in a bind

explore

WSS

Congenital heart disease patients face new threat of heart failure

A look at other Americans who have crossed into North Korea over the years

Flagship, Pfizer team up in deal worth up to $7 billion

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

What causes an itch? Researchers may have solved the mystery

Americans' trust in science, scientist continues decline: Report

entertainment

comprehensive

focus

How one medical school became remarkably diverse

Congenital heart disease patients face new threat of heart failure

Hollywood unions extend contract negotiations for actors

A Theranos scientist

Medicare proposal to cover medical devices draws a mixed reaction

Lack of darker skin in textbooks, journals harms patients of color

Heart attack and stroke risk calculators need revising

Lack of darker skin in textbooks, journals harms patients of color

Apple is now the first public company to be valued at $3 trillion

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

entertainment

Robert Kennedy Jr.'s presidential campaign attracts GOP

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

Why sickle cell disease is getting the first CRISPR treatment

DeSantis says Trump could've 'come out more forcefully' during Jan. 6

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

Why sickle cell disease is getting the first CRISPR treatment

knowledge

knowledge

explore

focus